It’s Thursday, healthcare enthusiasts.
Lots of large-scale M&A in healthcare over the past few days: The megadeal of the week goes to Centene for its $15.3 billion purchase of WellCare. In private equity highlights, there’s Ampersand Capital’s $1.7 billion sale of Boston’s Brammer Bio to Thermo Fisher.
But I’m just in from Boston, where I’ve been running around conferencing all week at Buyouts Insider’s PartnerConnect East. Here are some takeaways:
I got the chance to catch up with keynote speaker Dick Cashin, founder and president of One Equity Partners — and backer of healthcare companies including, in the U.S., home-care provider Simplura Health Group and post-acute healthcare-services company Ernest Health.
From a healthcare perspective, Cashin pointed to a handful of subsectors on the radar for OEP, the former middle-market PE arm of JP Morgan.
Areas of interest for New York’s OEP, he said: outsourced providers to skilled nursing facilities, revenue-cycle management, outsourced billing and payment services to capitated care providers, drug formulations and nutraceuticals, and drug and medical-product packaging.
Cashin, during his keynote on Tuesday, dove into how the OEP approach evolved largely out of its JPM roots. I’ll have more on that later today.
Speaking of healthcare packaging … ICYMI: Midwest-focused PE shop Mason Wells fielded first-round bids this week for Nelipak Healthcare Package, a provider of thermoformed packaging products for the medical-device and pharma industries. Read my full story for details on the process.
SUBSCRIBE to get the Healthcare Wire in your inbox every Thursday morning. It’s free!